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Abstract Single base substitutions can lead to missense
mutations, silent mutations or intronic mutations, whose
signiﬁcance is uncertain. Aberrant splicing can occur due to
mutations that disrupt or create canonical splice sites or
splicing regulatory sequences. The assessment of their
pathogenic role may be difﬁcult, and is further complicated
by the phenomenon of alternative splicing. We describe an
HNPCC patient, with early-onset colorectal cancer and a
strong family history of colorectal and breast tumors, who
harbours a germ line MLH1 intronic variant (IVS9 c.790
?4A[T). The proband, together with 2 relatives affected by
colorectal-cancer and 1 by breast cancer, have been inves-
tigated for microsatellite instability, immunohistochemical
MMR protein staining, direct sequencing and Multiplex
Ligation-dependent Probe Ampliﬁcation. The effect of the
intronic variant was analyzed both by splicing prediction
software and by hybrid minigene splicing assay. In this
family, we found a novel MLH1 germline intronic variant
(IVS9 c.790 ?4A[T) in intron 9, consisting of an A to T
transversion, in position ?4 of the splice donor site of
MLH1. The mutation is associated with the lack of
expression of the MLH1 protein and MSI in tumour tissues.
Furthermore, our results suggest that this substitution leads
toacompleteskipofbothexon9and10ofthemutantallele.
Our ﬁndings suggest that this intronic variant plays a path-
ogenic role.
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Hereditary Non-Polyposis Colorectal Cancer (HNPCC), or
Lynch syndrome, is an autosomal dominant inherited dis-
order that accounts for approximately 3–5% of all colo-
rectal cancers [1]. Lynch syndrome is associated with
germline mutations in MMR genes, in particular in MLH1
and MSH2, that have been found in up to 90% of HNPCC
patients, and less frequently in MSH6, PMS2 and MSH3
[2–4]. MMR deﬁciency leads to accumulation of replica-
tion errors, typically at short repetitive DNA sequences in
the tumour cells, giving rise to the molecular hallmark of
HNPCC: the microsatellite instability (MSI).
Individuals carrying germ line mutations of MMR genes
have a high lifetime risk of developing colorectal cancer as
well as an increased risk of tumours in extracolonic sites
such as endometrium, renal pelvis, ureter, stomach, small
intestine, bile ducts, ovary and possibly breast [5, 6]. Im-
munoistochemistry of MLH1 and MSH2 in tumour tissue
can be used as a complementary screening method, pro-
viding information about the presence or absence of the
protein tested and, thus the speciﬁc gene defect [7].
As mutations in MLH1 and MSH2 are spread throughout
the genes, without ‘‘hot spots’’, the detection of a predis-
posingmutationrequiresentiregenestobescreened.Todate
approximately 450 different mutations are listed in the
database of the International Society for Gastrointestinal
Hereditary Tumours (InSiGHT/LOVD database) (http://
www.insight-group.org/mutations/)[ 3].
Many of these mutations (*50%) lead to truncated
proteins (nonsense, frameshift, splice site mutations or
large genomic deletions), and are considered pathogenic.
However in Lynch syndrome families a substantial pro-
portion of MLH1 and MSH2 mutations are single nucleo-
tide substitutions, either within the coding sequence
(missense, or silent mutations) or in intronic regions.
Whether these mutations affect the normal function of
mismatch DNA repair proteins, and thus have a pathogenic
role, is an essential piece of information in genetic
counselling.
Traditionally, a missense mutation is considered more
likely to be pathogenic when a highly conserved amino acid
is involved, when its polarity is changed or when it is not
present in a large number of controls. More recent studies
have shown that some previously unclassiﬁed variants may
interferewithnormalsplicingprocess.Aberrantsplicingcan
occur due to mutations that disrupt the splice sites them-
selves or ESE or ESS motifs [8, 9, 12]. DNA mutations can
affect RNA processing by destroying or creating target
sequencesforsplicingregulatory proteins,thereby changing
the complex of factors bound to the pre-mRNA. This can
initially be assessed by bioinformatics methods that predict
the creation or the destruction of protein binding sites.
Here we describe the case of an HNPCC patient with a
strong family history, with a germ line MLH1 intronic
variant: intron 9 (IVS9 c.790 ?4A[T).
Patients and methods
Case report
The proband was a 24 year-old male (IV-1), diagnosed with
mucinous adenocarcinoma of the right colon when he was
24, and underwent right hemicolectomy (pT3N1M0, G3).
Detailed four generation family history was collected.
Overall, eight family members developed one or more
colorectal cancers and, interestingly, two had breast cancer.
The proband’s family showed a typical HNPCC (Lynch
syndrome) pedigree Fig. 1.
Tumour specimens of the proband and three relatives
(II-1, III-2, III-6) were available at the ‘‘Dipartimento di
Anatomia Patologica and were all examined by the same
pathologist (I.B.). The purpose of the study was explained,
and informed consent was obtained from participating
subjects. Ethics committee approval was obtained.
Microsatellite instability analysis
MSI was performed for the proband (IV-1) and relatives
II-1, III-2, III-6.
Genomic DNA was isolated from tumour samples and
corresponding normal tissues as previously described [14].
Tumours were examined for MSI using the 5-marker panel
recommendedbytheNationalCancerInstituteWorkshopon
MSI for Cancer Detection and Familial Predisposition [16].
Oligonucleotide primers were ﬂuorescently labelled (50-
VIC, 50-NED, 50-6-FAM, 50-6-FAM, 50-PET), MLH1 IVS9
c.790 ?4A[T and PCR products were evaluated with an
ABI Prism 310 Genetic Analyzer based on automated cap-
illary electrophoresis and automated sizing of the alleles by
GeneScan 3.7 (Applied Biosystems, Foster City, CA).
CAT25 microsatellite was also studied in all patients [17].
Expression of MLH1, MSH2, MSH6 and PMS2
proteins in tumour tissues
Tumour tissue was available for proband and patients II-1,
III-2, III-6.
Expression of the MLH1 and MSH2 proteins was
studied by immunohistochemistry (IHC) on 2-lm sections
of Formalin-Fixed, Parafﬁn-Embedded (FFPE) tissues,
following antigen retrieval as previously described [18].
Primary antibodies used for immunohistochemistry were:
anti-MLH1: clone G168-728, PharMingen, San Diego, CA,
1:50 dilution; anti-MSH2: clone FE11, Oncogene Research
Products, Cambridge, MA, 1:100 dilution; anti-MSH6:
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123clone H-141: sc-10798; Santa Cruz Biotechnology, Inc,
Santa Cruz, CA 1:250 dilution.
Mutation analysis of the MLH1, MSH2
and MSH6 genes
Mutation analysis was performed in patients IV-1 (pro-
band), II-1, III-2, III-5 and III-6 and in two healthy rela-
tives: III-1 and III-4.
Mutation analysis was performed on genomic DNA,
isolated from peripheral blood lymphocytes, according to
standard procedures. The 19 MLH1 exons, 16 MSH2 exons
and 10 MSH6 exons, including ﬂanking intronic regions,
were individually ampliﬁed and directly sequenced as
previously described [15]. Primer sequences are available
from the corresponding Author upon request [14].
Multiplex ligation-dependent probe ampliﬁcation
analysis
The patient was also studied by Multiplex Ligation-
dependent Probe Ampliﬁcation (MLPA) analysis.
MLPA was performedwith 200 ng of normal and tumour
DNAs using the MRC-Holland (Amsterdam, Holland)
MLH1/MSH2 and MSH6 SALSA MLPA Kits, according to
the supplier’s protocol and as previously described [15].
Splice site predictions
We used NNSPLICE 0.9 [19], NetGene2 [20], SpliceView
[21] and ASSP [22] tools for the splice sites predictions.
Among the tools to predict the ESE, ISS, ESS and ISE
motifs we use SpliceAid [23], ESEﬁnder [9], RESCUE-
ESE [24] and SplicingRainbow [25] tools. Many of these
tools form the Alamut 1.5 tool (www.interactive-bio
software.com).
MLH1 transcript analysis
Total RNA was puriﬁed from peripheral-blood lymphocytes
bytheRNeasyMiniKitandtheQIAampDNABloodMiniKit
(both from Qiagen, Hilden, Germany) according to the
instructionsofthemanufacturer.cDNAwassynthesizedfrom
2t o3lg by random hexamer-primed system for RT-PCR
(Invitrogen), according to the manufacture’s protocol. The
EX7-EX11fragmentwasobtainedaccordingtostandardPCR
protocols. Sequences of PCR primers are available from the
corresponding Author, primer forward (7F) 50-GTATTCA
GTACACAATGCAGG-30 and primer reverse (11R) 50-GC
ACATTCTGGGGACTGATTTC-30 [26]. The PCR cycling
conditions included the following cycles:1 cycle at 95Cf o r
5m i n ;3 5c y c l e sa t9 4 Cfor30 s,50Cfor30 s,and72Cfo r
30 s;1extensioncycleat72Cfor7 min.AliquotsoftheRT-
PCR products were separated on a 3% agarose gel and visu-
alized with ethidium bromide on an UV imaging system.
Bands, corresponding to shorter ampliﬁed fragments, were
excised from the gels and extracted by QIAquick Gel
ExtractionKit(Qiagen,hilden,Germany).ThepuriﬁedcDNA
fragments weresequenced directly,using AppliedBiosystem
ABI PRISM 310 automated sequencer and the Big Dye ter-
minator cycle sequencing Ready Reaction-Kit (Applied Bio-
systems),asdescribed.Theanalysiswasalsoconductedinthe
cDNA of normal controls.
Loss of heterozygosity analysis of tumor tissue
LOH analysis was performed in the colorectal cancer tissue
samples from the proband RNA (cDNA).
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Fig. 1 I-1: died at age 42 of colon cancer. II-1: 2 metachronous colon
cancers at age 48 and 82. II-2: died at age 76 of colon cancer (onset
age 74). II-3: died at age 62 of colon cancer (onset age 61). II-4: died
at age 47 of breast cancer. II-5: died at age 69 of colon cancer (onset
age 68). III-2: breast cancer (onset age 48). III-3: leukaemia. III-5:
colon cancer (onset age 52). III-6: 2 metachronous colon cancers at
age 31 and age 35. IV-1: colon cancer (onset age 24). Arrow indicates
the proband. Red borders indicate carrier status
An intronic mutation in MLH1 29
123Total tumor RNA was extracted from FFPE splices with,
in which 70% or more of tumor tissue, using Trizol (Invit-
rogen). After homogenization, proteinase K was added and
samples incubated at 55C for 30 min. Total RNA was
extracted according to the manufacturer’s instructions.
Samples were DNAse treated using Turbo DNAfree (Am-
bion) for 30 min at 37C. Reverse transcription was per-
formed from 2.6 lg of total RNA.
Tumor cDNA was ampliﬁed using the same primers
used for the MLH1 transcript analysis. The forward primer
was labelled with the NED Fluorochrome at the 50. The
PCR conditions are the same as in: ‘‘MLH1 transcript
analysis’’. The PCR products were subjected to fragment
analysis on ABI Prism 310 Genetic Analyzer based on
automated capillary electrophoresis and automated sizing
of the alleles by GeneScan 3.7 (Applied Biosystems). The
analysis was also carried out on a cDNA normal control.
The electropherograms were compared.
Hybrid minigene splicing assay
To generate the pCalfa Minigene construct, the alfa globin
gene from exon 1 to exon 3 was cloned in pCDNA3.1(?)
vector (Invitrogen) in two steps in order to retain the vector
single restriction sites EcoR1, BamH1 and Xho1 for the
following cloning. Human genomic DNA was ampliﬁed to
generate a fragment containing MLH1 exon 10 with inronic
ﬂanking sequences and cloned in pCalfa between BamH1
and Xho1 restriction sites. Patient genomic DNA was
ampliﬁed to generate fragments that contain MLH1 exon 9
wild-type (wt) and mutant with intronic ﬂanking sequences
and cloned in pCalfa between the EcoR1 and BamH1
restriction sites. The hybrid minigenes pCalfaMwt and
pCalfaM?4t were then analyzed for splicing. One micro-
gram of each minigene was transfected into 3 9 105 HeLa
cells with 5 ll Lipofectamine transfection Reagent (Invit-
rogen). Following RNA extraction (RNeasy plus kit, Qia-
gen)andRT-PCR(ReverseTranscriptionSystem,Promega)
the PCR analysis was performed using speciﬁc primers for
the pCalfa minigene. The size of the PCR ampliﬁed cDNA
bands obtained when analysed by agarose gel electropho-
resis will be the sum of each exon included in the transcript
which conﬁrms alternative splicing events.
Results
Microsatellite instability analysis
The proband (IV-I) showed high microsatellite instability
(MSI-H): three out of the ﬁve loci studied (Bethesda panel)
resulted altered. Similar results were observed in three
affected relatives: patient II-1 and patient III-2 exhibited
microsatellite instability in two out of the ﬁve markers
(MSI-H), patient III-6 showed microsatellite instability in
four out of the ﬁve markers (MSI-H). The CAT25 micro-
satellite analysis showed instability in the proband and in
relatives II-1, III-2, and III-6 (Table 1).
Expression of MLH1, MSH2 and MSH6 proteins
in tumour tissues
Study of protein expression was conducted in tumour
specimens of patients II-1, III-2, III-6 and IV-1 (proband).
In all cases, we observed lack of expression of MLH1 and
normal staining of MSH2 and MSH6 (Table 1; Fig. 2).
Mutation analysis of the MLH1, MSH2 and MSH6
genes
The sequence analysis of the entire coding regions of
MSH2 and MSH6 did not show any mutation. An intronic
variant was found in MLH1, IVS9 c.790 ?4A[T, an A to T
transversion, affecting position ?4 of the splice donor site
of MLH1/exon 9 (Fig. 3a). This variant was present in the
proband and his relatives II-1, III-2, III-5, III-6 (Fig. 1).
This mutation is not reported in InSiGHT/LOVD
mutation database and was not found in either 100 healthy
individuals, nor in 175 colorectal cancer patients.
The substitution has been searched for in two healthy
relatives: (III-1 and III-4) and was not detected (Table 1).
MLPA analysis
The MLPA analysis for MLH1 MSH2 and MSH6, did not
show any large genomic rearrangements.
Splice site prediction
Themutationstronglyweakensthe50 splicesiteaccordingto
NNSPLICE,NetGene2andSpliceViewtoolswhereasASSP
doesnotdetecteitherrealormutatedsite.Furtherpredictions
show that there are not strong cryptic 50 splice sites in a
window of 200 bp straddling the mutation so it seems more
probable the occurrence of an exon skipping rather than an
alternative50 splicesiteevent.SpliceAiddatabaseshowsthat
the mutation creates a binding sequence for ETR-3 splicing
factor over the 50 splice site [26, 27]. This prediction advises
the competition between ETR-3 and snRNP U1 factors for
recognition of the 50 splice site. ESEﬁnder, RESCUE-ESE
and Splicing Rainbow tools did not detect any alterations.
MLH1 transcript analysis
In the proband and in his relatives (with the mutation) we
RT-PCR ampliﬁed from peripheral lymphocyte cDNA, a
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123352 bp fragment of the MLH1 open reading frame (ORF),
including exons 7–11. In addition to the expected band
corresponding to the ampliﬁed product, we found two
lower molecular weight fragments: the 239-bp fragment,
lacking exon 9, and the 145 bp fragment, lacking boths
exon 9 and 10 (Fig. 3b, c). The band corresponding to
fragment lacking both exons 9 and 10 showed the same
intensity of the wt band, while the band corresponding to
fragment lacking exon 9, exhibited a weaker intensity.
We conducted the same analysis on cDNA from healthy
volunteers. In addition to the product ampliﬁed from full-
length cDNA, there were two other products, resulting
from the skipping of exon 9 and both exons 9 and 10, as in
patients’ cDNA.
However we found a signiﬁcant difference, in the pro-
portion of the three splicing isoforms. The patient’s cDNA,
showed two bands, wt and the skipping exons 9 ?10, with
the same intensity and a third band, corresponding to the
skipping of exon 9, with lower intensity. The control
cDNA showed three bands of different intensity: very high
for wt and signiﬁcantly lower for the fragments skipping
the exons 9 ?10 and exon 9 alone.
Loss of heterozygosity analysis of tumor tissue
Toclarifywhetherthepatient’stumorsamplesdisplayedallelic
loss,cDNAwasobtainedfromtumorandampliﬁedalongwith
cDNA from the patient’s normal tissue and from a normal
control. The tumor sample showed only the mutated product
(145 bp) with complete loss of the wt product. Ampliﬁcation
and Genescan analysis of cDNA from patient’s normal tissue
showed two alleles of equal heights (352 and 145 bp).
The cDNA of the healthy control showed a fragment
corresponding to wt transcript (352 bp) and two fragments
of less intensity: a fragment showing the same molecular
weight of mutated fragment of the tumor DNA (145 bp)
and a fragment showing a molecular weight corresponding
to deletion of MLH1 exon 9 (239 bp).
Hybrid minigene splicing assay
Transfection of the construct carrying the wild-type MLH1
intron 9 minigene (Fig. 4a), pCalfaM, in HeLa cells, fol-
lowed by RT-PCR ampliﬁcation generated a predominant
transcript of 646 bp containing exon 9 and exon 10
(Fig. 4b). The 439 and 552 bp bands consisted of exon 9
and 10 or exon 9 alone skipping analogous to that already
observed in tissues from normal individuals [11]. An
additional transcript of 799 bp was observed, representing
a splicing event where a cryptic 50ss, 101 nucleotides
upstream of the MLH1 exon 9 acceptor site is used instead
of the alfa globin exon 2 donor site. The activation of the
cryptic 50ss is not represented in nature.
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123Transfection of the mutant minigene pCalfaM_IVS9
?4A[T in HeLa cells showed aberrant splicing with a
minority of the transcript of 552 bp lacking exon 9 and the
majority lacking both exon 9 and exon 10 (Fig. 4b).
Discussion
Numerous mutations leading to truncated proteins have
been found in the mismatch repair genes MLH1 and MSH2
and are involved in Lynch syndrome.
Some patients carry DNA changes considered genetic
variants of unknown clinical signiﬁcance (Unclassiﬁed
Variants (UVs) with uncertainty about their cancer risks.
This is often the case for synonymous, missense and
intronic variants or when the nucleotide change affects or
creates a (putative) splice-site.
It is not easy to clarify whether an UV contributes to the
disease phenotype or merely represents a rare polymor-
phism. Several criteria are used to help in classifying these
variants as pathogenic, if they: (1) segregate with disease;
(2) are absent in controls; (3) result in a change of
Fig. 2 Immunohistochemical
staining for MLH1 (a), and
MSH2 (b), proteins showing
loss of MLH1 expression in the
proband’s colon cancer
Fig. 3 Sequence analysis of the MLH1 IVS9 c.790 ?4A[T. The
ﬁgure a shows the electropherogram of genomic DNA mutation. The
arrow indicate the intronic variation. The ﬁgures b and c shows the
electropherogram of wt cDNA (b), and the electropherogram of
cDNA fragment, lacking both exon 9 and 10 (c)
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123aminoacid polarity or size; (4) cause the substitution of an
amino acid in a domain that is evolutionary highly con-
served and/or is shared between proteins belonging to the
same protein family; (5) exhibit altered function in an in
vitro assay.
The correct classiﬁcation of an UV is of obvious
importance when assessing the cancer risk for the proband
and his family.
We report a MLH1 intronic mutation, in intron 9 donor
site (IVS9 c.790 ?4A[T) affecting the inclusion of both
exon 9 and exon 10.
The family studied fulﬁlled Amsterdam I criteria; all
affected family members, in which we could perform the
genetic test, carried the same MLH1 intronic mutation
(IVS9 c.790 ?4A[T). Moreover they all showed MSI-H
and the lack of expression of MLH1 protein in tumour
specimens. The mutation was not found in two unaffected
relatives of the proband and in 100 healthy individuals.
In this family there were two cases of breast cancer (II-
4, III-2). We could not examine a tumor specimen of the II-
4 patient (she died approximately 30 years ago), but she
was an obligate mutation carrier. Both cases of breast
cancer were diagnosed at an age compatible with what is
reported in literature for HNPCC associated breast cancers
[28–31]. The inclusion of breast cancer in HNPCC is
controversial but there are recent studies supporting this
hypothesis. Although breast cancer is a common tumor and
there may be phenocopies, approximately half of the cases
in HNPCC families [30, 31] show lack of staining for the
protein encoded by the mutated gene and the tumor sam-
ples show microsatellite instability (similar to our patient
III-2). It is of note that HNPCC associated breast cancers
seem to be more common in MLH1 mutated families [28].
The bioinformatic predictions show weakening of the 50
splice site. Generally, the weakening of a strong 50 splice
site makes the presence of additional alternative splicing
forms lacking an exon or with alternative 50 splice site
more probable. The lack of cryptic 50 splice sites near the
mutation supports the former event that is exon skipping.
Besides the weakening of the 50ss, the SpliceAid tool
prediction, showed the competition between ETR-3 and
snRNP U1 factors for recognition of the 50ss, enhances the
hypothesis that the mutation gives rise to exon 9 skipping
event in all alternative transcripts. Since the exon 9 length
is not a multiple of 3, its skipping event would give rise to a
frameshift resulting in premature stop codons. The intronic
mutation can therefore dramatically alter MLH1 exon 9
inclusion levels.
On the basis of the in silico predictions, we experi-
mentally investigated the presence of aberrant splicing due
to the IVS9c.790 ?4A[T mutation. The RNA analysis,
from blood lymphocytes of all patients considered, showed,
in addition to the wt band, one shorter fragment lacking
exons 9 ? 10 of and an additional band lacking exon 9.
Although several Authors have previously described
deletion of exon 9 ?10 and deletion of exon 9, as normal
alternative MLH1 transcripts [10, 13], their relative inten-
sity appeared signiﬁcantly lower than that of normal-sized
fragments (wt) [11].
The band corresponding to the deletion of exon 9 ?10,
from healthy subjects (100 controls) was of much lower
intensity than the band in our patient. Whilst in our pro-
band and his affected relatives the intensity of the bands
relative to cDNA products was equal between the wt gene
and the mutated gene A study of the functional role of the
deletion of exons 9 ?10, predicted that it does not con-
tribute to MMR function in vivo since it failed to restore
MMR in 293T [32].
Pagenstecher et al. published an intronic variant similar
to ours: c.790 ?4A[G, which showed high correlation
with phenotype, but they did not complete functional
studies and concluded that its pathogenicity was uncertain
[33].
In our proband the loss of heterozygosity analysis
showed complete loss of wt allele in cDNA from tumor
tissue and two alleles of equal molecular weight, corre-
sponding to the wt allele and to the mutant allele.
We also studied the effect of the IVS9c.790 ?4A[T
mutation by a functional splicing assay. Transient trans-
fection of the minigene carrying the patient mutation in
HeLa cells showed aberrant splicing with approximately
10% exon 9 skipping and 90% of both exons 9 and 10
M WT  MLH9+4A>T
pCalfaM
MLH1
CMV 
(a)
(b)
promoter
+4A>T
1
2
3 3
44
IVS9 c.790 +4A>T 
Fig. 4 Minigene Functional Splicing Assay. a The hybrid minigene
(pCalfaM) used in transient transfection splicing assays in HeLa cells
is shown. Exons are indicated as boxes. Introns are indicated as lines.
MLH1 Exon 9 and 10 (white and gray box) were tested for splicing
efﬁciency by using speciﬁc primers (arrows). b RT-PCR products
from transfection experiments. RNA splicing variants corresponding
to wt (2) exon 9 exclusion (3) and both exon 9 and 10 exclusion (4)
are shown. (1) indicate a splice variant generated as an artefact of the
minigene. M is the 100 bp marker
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123skipping. Although the results resemble the patients aber-
rant splicing in tumor affected tissue, transfection of the
minigene in other cell lines showed different proportions of
the splicing variants (data not shown) suggesting that there
is a strong inﬂuence of the splicing factors context on the
splicing outcome. We also detected a band in the wt
minigene corresponding to the partial retention of the
minigene intron between alfa globin exon 2 and MLH1
exon 3. The intron retention resulting from the activation of
a cryptic donor site, could be because of the altered
genomic context in the minigene system, as the cryptic
donor site is never used by the MLH1 endogenous gene.
The fact that we obtained similar results even in different
minigene contexts (data not shown) strongly suggests a
predisposition to disease caused by deep intronic variations
in MLH1 intron 8, since the creation of acceptor splice sites
upstream of the cryptic donor site may result in pseudo-
exon inclusion as observed for the minigene.
In conclusion, we studied one patient and three relatives
from a family with the hallmarks of HNPCC. All the
patients studied (three with colon cancer and one with
breast cancer) exhibited the same mutation and the labo-
ratory features are, in our opinion, compatible with the
pathogenicity of the c.790 ?4A[T mutation.
The reclassiﬁcation of this variant as deleterious has
signiﬁcant implications in the management of this family.
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